MicroPort CardioFlow Medtech Corporation (HKG:2160)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.660
-0.030 (-1.78%)
May 29, 2026, 4:08 PM HKT
Market Cap2.11B +0.7%
Revenue (ttm)444.00M +12.3%
Net Income-146.48M
EPS-0.30
Shares Out 1.27B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,534,216
Open1.700
Previous Close1.690
Day's Range1.630 - 1.740
52-Week Range1.640 - 8.450
Beta0.28
AnalystsStrong Buy
Price Target7.06 (+325.3%)
Earnings DateJun 4, 2026

About HKG:2160

MicroPort CardioFlow Medtech Corporation, together with its subsidiaries, researches, develops, manufactures, and sells medical devices for the treatment of structural heart disease and cardiac rhythm management in China, Europe, the Middle East, Africa, Asia, North America, and internationally. The company offers VitaFlow, a transcatheter aortic valve system; VitaFlow Liberty, a transcatheter aortic valve retrievable and controllable bend delivery system; Alwide, a plus valve balloon dilation catheter; AccuSniper, a double-layer balloon dilati... [Read more]

Sector Healthcare
Founded 2009
Employees 417
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2160
Full Company Profile

Financial Performance

In 2025, HKG:2160's revenue was $57.04 million, an increase of 12.28% compared to the previous year's $50.81 million. Losses were -$18.82 million, 170.9% more than in 2024.

Financial numbers in USD Financial Statements